John R. Kuhn

Learn More
J. Esquivel, R. Sticca, P. Sugarbaker, E. Levine, T. D. Yan, R. Alexander, D. Baratti, D. Bartlett, R. Barone, P. Barrios, S. Bieligk, P. Bretcha-Boix, C. K. Chang, F. Chu, Q. Chu, S. Daniel, E. deBree, M. Deraco, L. Dominguez-Parra, D. Elias, R. Flynn, J. Foster, A. Garofalo, F. N. Gilly, O. Glehen, A. Gomez-Portilla, L. Gonzalez-Bayon, S. Gonzalez-Moreno,(More)
Recent research has focused heavily on the practicality and feasibility of alternative architectures for supporting continuous auditing. In this paper, we explore the alternative architectures for continuous auditing that have been proposed in both the research and practice environments. We blend a focus on the practical realities of the current(More)
P. E. Bosted,35,* R. Fersch,39 G. Adams,31 M. Amarian,29 S. Anefalos,17 M. Anghinolfi,18 G. Asryan,40 H. Avakian,17,35 H. Bagdasaryan,29,40 N. Baillie,39 J. P. Ball,2 N. A. Baltzell,34 S. Barrow,13 V. Batourine,35 M. Battaglieri,18 K. Beard,21 I. Bedlinskiy,20 M. Bektasoglu,29 M. Bellis,5,31 N. Benmouna,14 A. S. Biselli,11 B. E. Bonner,32 S. Bouchigny,19,35(More)
I. Hleiqawi,1 K. Hicks,1 D. S. Carman,1,32 T. Mibe,1 G. Niculescu,20 A. Tkabladze,13 M. Amarian,26 P. Ambrozewicz,11 M. Anghinolfi,17 G. Asryan,37 H. Avakian,32 H. Bagdasaryan,26 N. Baillie,36 J. P. Ball,2 N. A. Baltzell,31 V. Batourine,21 M. Battaglieri,17 K. Beard,20 I. Bedlinskiy,19 M. Bellis,4 N. Benmouna,13 B. L. Berman,13 A. S. Biselli,4 S.(More)
PURPOSE Maintaining dose-intensity with chemotherapeutic agents is hindered by a number of adverse effects including asthenia/fatigue. Tumor necrosis factor (TNF) is one of the cytokines responsible for the fatigue and cachexia associated with malignancies. We used etanercept (TNF-decoy receptor) to maintain dose-intensity of weekly docetaxel. PATIENTS(More)
Purpose: Nuclear factor-κB (NF-κB) activation induces resistance to irinotecan. Preclinically, thalidomide and COX-2 inhibitors reduce NF-κB activation. We tested the feasibility of combining irinotecan with thalidomide and thalidomide/celecoxib in patients with refractory malignancies. Patients/methods: The study was conducted in two parts. First, the(More)
Circulating tumor cells (CTCs) have recently been shown to be an independent predictor of progression-free and overall survival in patients undergoing treatment for metastatic breast cancer. This study evaluates the presence and significance of CTCs in patient undergoing surgical resection of clinically localized primary breast cancer. Patients undergoing(More)
OBJECTIVE Open repair of descending thoracic aortic and thoracoabdominal aortic aneurysms may carry low morbidity and mortality, depending on experience of the surgeon and operative technique used. Although thoracic endovascular aortic repair is less invasive, its limitations include anatomy and pathology of the aorta, proximity of major branches, and(More)